Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

XAIR – Beyond Air Inc

Float Short %

3.14

Margin Of Safety %

Put/Call OI Ratio

0.03

EPS Next Q Diff

0.98

EPS Last/This Y

10.5

EPS This/Next Y

1.95

Price

1.76

Target Price

10.33

Analyst Recom

1.5

Performance Q

-27.16

Relative Volume

0.1

Beta

0.28

Ticker: XAIR




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26XAIR0.768N/AN/A0
2025-12-29XAIR0.7299N/AN/A0
2025-12-30XAIR0.6975N/AN/A0
2025-12-31XAIR0.7332N/AN/A0
2026-01-02XAIR0.796N/AN/A0
2026-01-05XAIR0.8333N/AN/A0
2026-01-06XAIR0.790.00999.993670
2026-01-07XAIR0.820.000.003663
2026-01-08XAIR0.94310.000.003663
2026-01-09XAIR0.88510.000.003663
2026-01-12XAIR0.8630.000.003663
2026-01-13XAIR2.080.000.283664
2026-01-14XAIR1.860.030.004289
2026-01-15XAIR1.720.03999.994384
2026-01-16XAIR1.730.03609.004384
2026-01-20XAIR1.950.03703.004384
2026-01-21XAIR1.8350.03703.004384
2026-01-22XAIR1.7650.03703.004384
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26XAIR0.76- - -3.30
2025-12-29XAIR0.70- - -3.30
2025-12-30XAIR0.70- - -3.30
2025-12-31XAIR0.73- - -3.30
2026-01-02XAIR0.78- - -3.30
2026-01-05XAIR0.82- - -3.30
2026-01-06XAIR0.79- - -3.30
2026-01-07XAIR0.82- - -3.30
2026-01-08XAIR0.95- - -3.30
2026-01-09XAIR0.88- - -3.30
2026-01-12XAIR0.87- - -3.30
2026-01-13XAIR2.16- - -3.30
2026-01-14XAIR1.85- - -3.30
2026-01-15XAIR1.73- - -3.30
2026-01-16XAIR1.72- - -3.30
2026-01-20XAIR1.98- - -3.30
2026-01-21XAIR1.84- - -3.30
2026-01-22XAIR1.76- - -3.30
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26XAIR1.322.473.88
2025-12-29XAIR1.322.473.89
2025-12-30XAIR1.292.473.89
2025-12-31XAIR1.292.473.89
2026-01-02XAIR1.292.473.89
2026-01-05XAIR1.292.473.89
2026-01-06XAIR1.292.473.89
2026-01-07XAIR1.292.473.89
2026-01-08XAIR1.292.473.89
2026-01-09XAIR1.292.473.89
2026-01-12XAIR1.20-2.603.89
2026-01-13XAIR1.29-2.603.14
2026-01-14XAIR1.29-2.603.14
2026-01-15XAIR1.29-2.603.14
2026-01-16XAIR1.29-2.603.14
2026-01-20XAIR1.29-2.603.14
2026-01-21XAIR1.29-2.603.14
2026-01-22XAIR1.29-2.603.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-1.25

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.27

Insider Transactions

1.29

Institutional Transactions

-2.6

Beta

0.28

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

14

Growth Score

39

Sentiment Score

42

Actual DrawDown %

99.5

Max Drawdown 5-Year %

-99.8

Target Price

10.33

P/E

Forward P/E

PEG

P/S

2.44

P/B

1.11

P/Free Cash Flow

EPS

-7.53

Average EPS Est. Cur. Y​

-3.3

EPS Next Y. (Est.)

-1.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-632.51

Relative Volume

0.1

Return on Equity vs Sector %

-315.5

Return on Equity vs Industry %

-305.9

EPS 1 7Days Diff

-1

EPS 1 30Days Diff

-1.05

EBIT Estimation

Beyond Air, Inc.
Sector: Healthcare
Industry: Medical Devices
Employees: 61
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
stock quote shares XAIR – Beyond Air Inc Stock Price stock today
news today XAIR – Beyond Air Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch XAIR – Beyond Air Inc yahoo finance google finance
stock history XAIR – Beyond Air Inc invest stock market
stock prices XAIR premarket after hours
ticker XAIR fair value insiders trading

OPGN – Opgen Inc

Float Short %

1.02

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

18.59

Target Price

Analyst Recom

3

Performance Q

-57.39

Relative Volume

Beta

-0.64

Ticker: OPGN




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26OPGN14.95N/AN/A0
2025-12-29OPGN15.73N/AN/A0
2025-12-30OPGN15.7N/AN/A0
2025-12-31OPGN15.9N/AN/A0
2026-01-02OPGN16.7N/AN/A0
2026-01-05OPGN16.5N/AN/A0
2026-01-06OPGN16.37N/AN/A0
2026-01-07OPGN17.9999N/AN/A0
2026-01-08OPGN17.8N/AN/A0
2026-01-09OPGN17.8N/AN/A0
2026-01-12OPGN17.89N/AN/A0
2026-01-13OPGN18.7N/AN/A0
2026-01-14OPGN18.9N/AN/A0
2026-01-15OPGN18.81N/AN/A0
2026-01-16OPGN16.8N/AN/A0
2026-01-20OPGN15.5N/AN/A0
2026-01-21OPGN16.5N/AN/A0
2026-01-22OPGN16.51N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26OPGN11.20- - -
2025-12-29OPGN11.35- - -
2025-12-30OPGN11.81- - -
2025-12-31OPGN15.65- - -
2026-01-02OPGN16.05- - -
2026-01-05OPGN16.00- - -
2026-01-06OPGN14.80- - -
2026-01-07OPGN13.30- - -
2026-01-08OPGN17.80- - -
2026-01-09OPGN17.80- - -
2026-01-12OPGN17.69- - -
2026-01-13OPGN15.62- - -
2026-01-14OPGN16.10- - -
2026-01-15OPGN16.51- - -
2026-01-16OPGN16.81- - -
2026-01-20OPGN16.00- - -
2026-01-21OPGN16.50- - -
2026-01-22OPGN18.59- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




No data found

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

-0.64

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

100

Growth Score

Sentiment Score

82

Actual DrawDown %

7

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

6.13

P/B

P/Free Cash Flow

EPS

-40.32

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

38.8

Return on Equity vs Industry %

48.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

OpGen, Inc.
Sector: Healthcare
Industry: Medical Devices
Employees: 1
OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. In addition, the company offers listing sponsorship and consultancy services. OpGen, Inc. was incorporated in 2001 and is based in Clarksburg, Maryland.
stock quote shares OPGN – Opgen Inc Stock Price stock today
news today OPGN – Opgen Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch OPGN – Opgen Inc yahoo finance google finance
stock history OPGN – Opgen Inc invest stock market
stock prices OPGN premarket after hours
ticker OPGN fair value insiders trading

OFIX – Orthofix Medical Inc

Float Short %

2.61

Margin Of Safety %

Put/Call OI Ratio

0.55

EPS Next Q Diff

0.43

EPS Last/This Y

3.99

EPS This/Next Y

-0.27

Price

13.83

Target Price

21.33

Analyst Recom

1.5

Performance Q

-12.02

Relative Volume

0.76

Beta

0.79

Ticker: OFIX




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26OFIX15.25N/AN/A0
2025-12-29OFIX15.47N/AN/A0
2025-12-30OFIX15.32N/AN/A0
2025-12-31OFIX15.150.690.00206
2026-01-02OFIX14.850.68999.99208
2026-01-05OFIX15.350.600.00199
2026-01-06OFIX15.590.600.00200
2026-01-07OFIX15.720.600.00200
2026-01-08OFIX16.180.600.00200
2026-01-09OFIX15.770.560.00210
2026-01-12OFIX15.260.520.00220
2026-01-13OFIX14.790.520.00220
2026-01-14OFIX14.340.51999.99221
2026-01-15OFIX14.390.51999.99221
2026-01-16OFIX14.070.51999.99221
2026-01-20OFIX13.650.55999.99225
2026-01-21OFIX13.850.55999.99225
2026-01-22OFIX13.810.55999.99225
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26OFIX15.252762.7- 0.69
2025-12-29OFIX15.472762.7- 0.69
2025-12-30OFIX15.322762.7- 0.69
2025-12-31OFIX15.142762.7- 0.69
2026-01-02OFIX14.852762.7- 0.69
2026-01-05OFIX15.342762.7- 0.69
2026-01-06OFIX15.592762.7- 0.69
2026-01-07OFIX15.722762.7- 0.69
2026-01-08OFIX16.192762.7- 0.69
2026-01-09OFIX15.762762.7- 0.69
2026-01-12OFIX15.282762.7- 0.69
2026-01-13OFIX14.812762.7- 0.69
2026-01-14OFIX14.342762.7- 0.69
2026-01-15OFIX14.372762.7- 0.69
2026-01-16OFIX14.062762.7- 0.69
2026-01-20OFIX13.652762.7- 0.69
2026-01-21OFIX13.852762.7- 0.69
2026-01-22OFIX13.832762.7- 0.69
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26OFIX-0.10-0.952.94
2025-12-29OFIX-0.10-0.962.94
2025-12-30OFIX-0.10-0.962.94
2025-12-31OFIX-0.10-0.962.94
2026-01-02OFIX-0.10-0.962.94
2026-01-05OFIX-0.10-0.962.94
2026-01-06OFIX-0.10-0.962.94
2026-01-07OFIX-0.10-0.962.94
2026-01-08OFIX-0.26-0.962.94
2026-01-09OFIX-0.26-0.962.94
2026-01-12OFIX-0.25-0.962.94
2026-01-13OFIX-0.26-0.962.61
2026-01-14OFIX-2.67-0.962.61
2026-01-15OFIX-2.67-0.962.61
2026-01-16OFIX-2.67-0.962.61
2026-01-20OFIX-2.67-1.072.61
2026-01-21OFIX-3.34-1.072.61
2026-01-22OFIX-3.34-1.072.61
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.57

Avg. EPS Est. Current Quarter

0.44

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

-3.34

Institutional Transactions

-1.07

Beta

0.79

Average Sales Estimate Current Quarter

218

Average Sales Estimate Next Quarter

199

Fair Value

Quality Score

45

Growth Score

49

Sentiment Score

33

Actual DrawDown %

71.5

Max Drawdown 5-Year %

-79.8

Target Price

21.33

P/E

Forward P/E

PEG

P/S

0.67

P/B

1.24

P/Free Cash Flow

EPS

-3.04

Average EPS Est. Cur. Y​

0.69

EPS Next Y. (Est.)

0.42

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14.56

Relative Volume

0.76

Return on Equity vs Sector %

-54.2

Return on Equity vs Industry %

-44.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.15

EBIT Estimation

Orthofix Medical Inc.
Sector: Healthcare
Industry: Medical Devices
Employees: 1616
Orthofix Medical Inc. operates as a medical technology company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulation devices that enhance bone fusion, including adjunctive and noninvasive treatment of the cervical and lumbar spine, as well as a therapeutic treatment for non-spinal, appendicular fractures, and fresh fractures that have not healed; designs, develops, and markets a portfolio of spine fixation and motion preservation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and provides 7D flash navigation system for spine and cranial procedures. Its Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
stock quote shares OFIX – Orthofix Medical Inc Stock Price stock today
news today OFIX – Orthofix Medical Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch OFIX – Orthofix Medical Inc yahoo finance google finance
stock history OFIX – Orthofix Medical Inc invest stock market
stock prices OFIX premarket after hours
ticker OFIX fair value insiders trading

MDT – Medtronic Plc

Float Short %

1.12

Margin Of Safety %

9

Put/Call OI Ratio

0.43

EPS Next Q Diff

0.33

EPS Last/This Y

0.16

EPS This/Next Y

0.46

Price

101.32

Target Price

111.65

Analyst Recom

2

Performance Q

5.75

Relative Volume

1.43

Beta

0.72

Ticker: MDT




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26MDT96.540.540.82189384
2025-12-29MDT96.140.540.34187033
2025-12-30MDT96.690.530.19188116
2025-12-31MDT96.070.520.54191244
2026-01-02MDT96.050.520.30189488
2026-01-05MDT97.390.510.24184303
2026-01-06MDT100.30.510.25187755
2026-01-07MDT99.750.500.31191482
2026-01-08MDT98.680.500.42193646
2026-01-09MDT97.530.500.95195658
2026-01-12MDT96.910.530.32191874
2026-01-13MDT96.430.520.35197780
2026-01-14MDT98.740.520.57198734
2026-01-15MDT98.960.530.39202123
2026-01-16MDT96.760.530.17203906
2026-01-20MDT98.60.450.20134760
2026-01-21MDT100.280.440.21142585
2026-01-22MDT101.330.430.14144820
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26MDT96.53-4.0832.15.65
2025-12-29MDT96.14-4.0855.45.65
2025-12-30MDT96.68-4.0913.75.65
2025-12-31MDT96.08-4.0842.25.65
2026-01-02MDT96.04-4.0878.35.65
2026-01-05MDT97.39-4.01799.05.65
2026-01-06MDT100.32-4.01913.35.65
2026-01-07MDT99.73-4.01661.55.65
2026-01-08MDT98.68-4.01625.65.65
2026-01-09MDT97.54-4.01620.65.65
2026-01-12MDT96.91-4.01657.65.65
2026-01-13MDT96.43-4.01664.35.65
2026-01-14MDT98.74-4.01868.95.65
2026-01-15MDT98.96-4.01717.75.65
2026-01-16MDT96.76-4.01544.15.65
2026-01-20MDT98.60-4.01834.05.65
2026-01-21MDT100.29-4.01821.35.65
2026-01-22MDT101.32-4.01773.65.65
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26MDT-3.170.601.18
2025-12-29MDT-3.170.601.18
2025-12-30MDT-3.170.601.18
2025-12-31MDT-3.170.601.18
2026-01-02MDT-3.170.601.18
2026-01-05MDT-3.170.631.18
2026-01-06MDT-3.170.631.18
2026-01-07MDT-3.170.631.18
2026-01-08MDT-3.170.631.18
2026-01-09MDT-3.170.631.18
2026-01-12MDT-3.140.641.18
2026-01-13MDT-3.170.641.12
2026-01-14MDT-3.170.641.12
2026-01-15MDT-3.170.641.12
2026-01-16MDT-3.170.641.12
2026-01-20MDT-3.171.731.12
2026-01-21MDT-3.171.731.12
2026-01-22MDT-3.171.731.12
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

1.36

Avg. EPS Est. Current Quarter

1.33

Avg. EPS Est. Next Quarter

1.69

Insider Transactions

-3.17

Institutional Transactions

1.73

Beta

0.72

Average Sales Estimate Current Quarter

8894

Average Sales Estimate Next Quarter

9642

Fair Value

110.65

Quality Score

84

Growth Score

87

Sentiment Score

97

Actual DrawDown %

25.4

Max Drawdown 5-Year %

-45.1

Target Price

111.65

P/E

27.38

Forward P/E

16.55

PEG

2.67

P/S

3.74

P/B

2.67

P/Free Cash Flow

24.96

EPS

3.7

Average EPS Est. Cur. Y​

5.65

EPS Next Y. (Est.)

6.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.71

Relative Volume

1.43

Return on Equity vs Sector %

-17.5

Return on Equity vs Industry %

-7.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

1773.6
Medtronic plc.
Sector: Healthcare
Industry: Medical Devices
Employees: 95000
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
stock quote shares MDT – Medtronic Plc Stock Price stock today
news today MDT – Medtronic Plc stock forecast ,stock prediction 2023 2024 2025
marketwatch MDT – Medtronic Plc yahoo finance google finance
stock history MDT – Medtronic Plc invest stock market
stock prices MDT premarket after hours
ticker MDT fair value insiders trading

IRMD – Iradimed Corp

Float Short %

5.28

Margin Of Safety %

-26

Put/Call OI Ratio

1.03

EPS Next Q Diff

0.03

EPS Last/This Y

0.35

EPS This/Next Y

0.25

Price

103.91

Target Price

99

Analyst Recom

1

Performance Q

38.33

Relative Volume

0.79

Beta

1.1

Ticker: IRMD




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26IRMD97.591.09999.99649
2025-12-29IRMD97.791.101.67650
2025-12-30IRMD97.771.101.67650
2025-12-31IRMD97.371.0920.00651
2026-01-02IRMD95.641.0920.00651
2026-01-05IRMD98.691.140.00668
2026-01-06IRMD98.291.070.00688
2026-01-07IRMD98.321.080.00686
2026-01-08IRMD99.941.050.00695
2026-01-09IRMD98.951.070.00688
2026-01-12IRMD97.781.070.00689
2026-01-13IRMD99.211.0231.00706
2026-01-14IRMD101.461.10999.99738
2026-01-15IRMD102.451.130.14748
2026-01-16IRMD101.961.120.44769
2026-01-20IRMD103.131.252.86609
2026-01-21IRMD103.361.100.15683
2026-01-22IRMD103.871.035.00709
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26IRMD97.469.1- 1.86
2025-12-29IRMD97.719.1- 1.86
2025-12-30IRMD97.589.1- 1.86
2025-12-31IRMD97.189.1- 1.86
2026-01-02IRMD95.429.1- 1.86
2026-01-05IRMD98.339.1- 1.86
2026-01-06IRMD98.479.1- 1.86
2026-01-07IRMD98.189.1- 1.86
2026-01-08IRMD99.919.1- 1.86
2026-01-09IRMD98.939.1- 1.86
2026-01-12IRMD97.809.1- 1.86
2026-01-13IRMD99.209.1- 1.86
2026-01-14IRMD101.699.1- 1.86
2026-01-15IRMD102.399.1- 1.86
2026-01-16IRMD101.949.1- 1.86
2026-01-20IRMD103.039.1- 1.86
2026-01-21IRMD103.269.1- 1.86
2026-01-22IRMD103.919.1- 1.86
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26IRMD-2.29-0.093.82
2025-12-29IRMD-2.29-0.093.82
2025-12-30IRMD-2.39-0.093.82
2025-12-31IRMD-2.39-0.093.82
2026-01-02IRMD-2.39-0.093.82
2026-01-05IRMD-2.390.003.82
2026-01-06IRMD-2.500.003.82
2026-01-07IRMD-2.500.003.82
2026-01-08IRMD-2.500.003.82
2026-01-09IRMD-2.500.003.82
2026-01-12IRMD-2.500.003.82
2026-01-13IRMD-2.600.004.77
2026-01-14IRMD-2.600.004.77
2026-01-15IRMD-2.600.004.77
2026-01-16IRMD-2.600.004.77
2026-01-20IRMD-2.600.464.77
2026-01-21IRMD-2.710.464.77
2026-01-22IRMD-2.710.465.28
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

0.43

Avg. EPS Est. Current Quarter

0.48

Avg. EPS Est. Next Quarter

0.46

Insider Transactions

-2.71

Institutional Transactions

0.46

Beta

1.1

Average Sales Estimate Current Quarter

21

Average Sales Estimate Next Quarter

20

Fair Value

76.51

Quality Score

91

Growth Score

97

Sentiment Score

98

Actual DrawDown %

0.1

Max Drawdown 5-Year %

-49.4

Target Price

99

P/E

62.94

Forward P/E

49

PEG

4.59

P/S

16.42

P/B

13.44

P/Free Cash Flow

89.6

EPS

1.65

Average EPS Est. Cur. Y​

1.86

EPS Next Y. (Est.)

2.12

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

26.31

Relative Volume

0.79

Return on Equity vs Sector %

-5.7

Return on Equity vs Industry %

3.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

iRadimed Corporation
Sector: Healthcare
Industry: Medical Devices
Employees: 160
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
stock quote shares IRMD – Iradimed Corp Stock Price stock today
news today IRMD – Iradimed Corp stock forecast ,stock prediction 2023 2024 2025
marketwatch IRMD – Iradimed Corp yahoo finance google finance
stock history IRMD – Iradimed Corp invest stock market
stock prices IRMD premarket after hours
ticker IRMD fair value insiders trading

IRIX – IRIDEX Corp.

Float Short %

2.4

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

1.5

Target Price

2

Analyst Recom

3

Performance Q

37.96

Relative Volume

2.25

Beta

0.69

Ticker: IRIX




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26IRIX1.21N/AN/A0
2025-12-29IRIX1.18N/AN/A0
2025-12-30IRIX1.150.000.00160
2025-12-31IRIX1.120.000.00160
2026-01-02IRIX1.180.000.00160
2026-01-05IRIX1.210.000.00160
2026-01-06IRIX1.170.000.00160
2026-01-07IRIX1.19N/AN/A0
2026-01-08IRIX1.205N/AN/A0
2026-01-09IRIX1.15N/AN/A0
2026-01-12IRIX1.490.000.00165
2026-01-13IRIX1.3750.000.00167
2026-01-14IRIX1.320.000.00167
2026-01-15IRIX1.36780.000.00167
2026-01-16IRIX1.43140.000.00171
2026-01-20IRIX1.490.000.0017
2026-01-21IRIX1.570.000.0018
2026-01-22IRIX1.50.000.0018
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26IRIX1.20- - -
2025-12-29IRIX1.17- - -
2025-12-30IRIX1.15- - -
2025-12-31IRIX1.13- - -
2026-01-02IRIX1.18- - -
2026-01-05IRIX1.21- - -
2026-01-06IRIX1.18- - -
2026-01-07IRIX1.19- - -
2026-01-08IRIX1.20- - -
2026-01-09IRIX1.15- - -
2026-01-12IRIX1.49- - -
2026-01-13IRIX1.38- - -
2026-01-14IRIX1.31- - -
2026-01-15IRIX1.36- - -
2026-01-16IRIX1.42- - -
2026-01-20IRIX1.49- - -
2026-01-21IRIX1.58- - -
2026-01-22IRIX1.50- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26IRIX2.361.782.35
2025-12-29IRIX2.361.792.35
2025-12-30IRIX2.361.792.35
2025-12-31IRIX2.361.792.35
2026-01-02IRIX2.361.792.35
2026-01-05IRIX2.361.792.35
2026-01-06IRIX2.361.792.35
2026-01-07IRIX2.361.792.35
2026-01-08IRIX2.361.792.35
2026-01-09IRIX2.361.792.35
2026-01-12IRIX2.281.792.42
2026-01-13IRIX2.211.792.40
2026-01-14IRIX2.211.792.40
2026-01-15IRIX2.211.792.40
2026-01-16IRIX2.211.792.40
2026-01-20IRIX2.272.242.40
2026-01-21IRIX2.352.242.40
2026-01-22IRIX2.352.242.40
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.09

Avg. EPS Est. Next Quarter

Insider Transactions

2.35

Institutional Transactions

2.24

Beta

0.69

Average Sales Estimate Current Quarter

12

Average Sales Estimate Next Quarter

Fair Value

Quality Score

21

Growth Score

34

Sentiment Score

73

Actual DrawDown %

84.6

Max Drawdown 5-Year %

-91.6

Target Price

2

P/E

Forward P/E

PEG

P/S

0.51

P/B

P/Free Cash Flow

EPS

-0.3

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-10.04

Relative Volume

2.25

Return on Equity vs Sector %

-135.9

Return on Equity vs Industry %

-126.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

IRIDEX Corporation
Sector: Healthcare
Industry: Medical Devices
Employees: 93
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
stock quote shares IRIX – IRIDEX Corp. Stock Price stock today
news today IRIX – IRIDEX Corp. stock forecast ,stock prediction 2023 2024 2025
marketwatch IRIX – IRIDEX Corp. yahoo finance google finance
stock history IRIX – IRIDEX Corp. invest stock market
stock prices IRIX premarket after hours
ticker IRIX fair value insiders trading
No more stocks to show